Laryngeal Cancer Pipeline Review, H2 2012


#146092

69pages

Global Markets Direct

$ 2000

In Stock


Laryngeal Cancer Pipeline Review, H2 2012

Global Markets Directs, 'Laryngeal Cancer Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Laryngeal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Laryngeal Cancer. Laryngeal Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Laryngeal Cancer.
  • A review of the Laryngeal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Laryngeal Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Laryngeal Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Laryngeal Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Laryngeal Cancer Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Laryngeal Cancer 8
Laryngeal Cancer Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Laryngeal Cancer Therapeutics Products under Investigation by Universities/Institutes 16
Laryngeal Cancer Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Combination Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
HPPH - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
5-Fluorouracil + Hydroxyurea + Bevacizumab + Radiation Therapy - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Fludarabine + Radiation Therapy - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Radiation Therapy + Cetuximab - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
celecoxib - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Cisplatin + Erlotinib + Radiation Therapy - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Cetuximab + Cisplatin + Radiation Therapy - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 34
S-1 + Radiation Therapy - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
S-1 + Radiation Therapy - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Docetaxel + 5-Fluorouracil + Cisplatin + Cetuximab + Radiation Therapy - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Docetaxel + Radiation Therapy - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Carbogen + Nicotinamide + Radiotherapy - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Cisplatin + 5FU + Taxotere - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Cisplatin + Fluorouracil + Docetaxel + Cetuximab - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 45
Cisplatin + Cetuximab + 5-Fluorouracil + Taxotere + Radiation Therapy - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Erlotinib Hydrochloride + Radiation Therapy - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Cisplatin - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Lapatinib Ditosylate + Capecitabine - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Erbitux + Radiation Therapy - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Taxotere + Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Docetaxel + Cisplatin + 5-Fluorouracil + Erbitux + Radiation Therapy - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 57
Docetaxel + Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 59
Docetaxel + Cisplatin + 5-Fluorouracil + Cetuximab + Radiation Therapy - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 61
S-1 + Radiation Therapy - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
AT-101 + Docetaxel + Cisplatin - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Laryngeal Cancer Therapeutics Drug Profile Updates 64
Laryngeal Cancer Therapeutics Discontinued Products 66
Laryngeal Cancer Therapeutics - Dormant Products 67

Appendix 68
Methodology 68
Coverage 68
Secondary Research 68
Primary Research 68
Expert Panel Validation 68
Contact Us 69
Disclaimer 69

Number of Products Under Development for Laryngeal Cancer, H2 2012 8
Products under Development for Laryngeal Cancer Comparative Analysis, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 12
Comparative Analysis by Late Stage Development, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Comparative Analysis by Early Clinical Stage Development, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
Assessment by Monotherapy Products, H2 2012 17
Assessment by Combination Products, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 22
Laryngeal Cancer Therapeutics Drug Profile Updates 64
Laryngeal Cancer Therapeutics Discontinued Products 66
Laryngeal Cancer Therapeutics Dormant Products 67
Number of Products under Development for Laryngeal Cancer, H2 2012 8
Products under Development for Laryngeal Cancer Comparative Analysis, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 13
Mid Clinical Stage Products, H2 2012 14
Early Clinical Stage Products, H2 2012 15
Assessment by Monotherapy Products, H2 2012 17
Assessment by Combination Products, H2 2012 18
Assessment by Route of Administration, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Molecule Type, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 22